BLRX

BioLineRx Ltd develops therapeutics for oncology and rare diseases. The company focuses on advancing drug candidates through clinical development, including APHEXDA® (motixafortide), a stem cell mobilization agent that has received FDA approval and is commercially launched. BioLineRx is also developing GLIX1, an oral small molecule targeting the DNA damage response in cancer cells, with applications in glioblastoma and other cancer indications. Additionally, the company collaborates with Columbia and Regeneron on a Phase 2b study for pancreatic ductal adenocarcinoma.